Navigation Links
Fougera First-to-Market With Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution)

MELVILLE, N.Y., May 6 /PRNewswire/ -- Today, Fougera, a division of Nycomed US Inc., announced it has received FDA approval to bring to market the first generic Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution). The generic formulation compares to Dovonex(R) by Warner-Chilcott.

(Photo: )

Fougera's Calcipotriene Topical Solution is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp (see product package insert for full prescribing information). It is available in a 60 mL bottle (NDC # 0168-0400-60).

"Fougera has received more FDA approvals for topical products during the past seven years than any other generic company. Today's announcement that we are first-to-market with Calcipotriene Topical Solution is another example of our ongoing commitment to provide safe, effective and affordable options to health care providers and their patients," stated David Klaum, Senior Vice President, Commercial Business Operations.

Founded in 1849, Fougera is the largest of the three Nycomed US Inc. divisions and is the leading manufacturer and distributor of a wide range of topical steroids, antibiotics and antifungal products. For more information on Fougera's complete line of products, please call Fougera Customer Service at (800) 645-9833 or visit the company online at

About Nycomed US

Nycomed US, Inc. (formerly ALTANA Inc) is a subsidiary of Nycomed, and also operates two additional divisions in the US focused on specialty pharmaceuticals in dermatology. The PharmaDerm(R) division of Nycomed is dedicated to bringing innovative products to the dermatologists so they can best care for their patients. Nycomed US, Inc. and its PharmaDerm Division recently announced the acquisition of Bradley Pharmaceuticals, a global specialty company with 3 divisions-Doak Dermatologics, Kenwood Therapeutics, and A. Aarons. The Bradley product line will be combined with the current offerings of PharmaDerm, enabling the Company to offer more therapeutic choices and enhanced customer service. Combined with Nycomed's Fougera Division, Nycomed becomes a leader in the dermatology market. Nycomed US also markets and sells Savage Laboratories products, which focus on emergency care.

SOURCE Fougera
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
2. Topical Cream Treats Precancerous Lesions of Vulva
3. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
4. International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as its First and Only Official Joint and Muscle Topical Cream
5. Summit VetPharm Introduces New Feline Topicals Vectra(TM) for Cats & Kittens and Vectra(TM) for Cats
6. Topical treatment for age spots, from Harvard Womens Health Watch
7. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
8. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
9. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
10. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
11. UHW Outlines Solutions to Californias Health Crisis
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
(Date:11/27/2015)... Santa Rosa, CA (PRWEB) , ... November 27, 2015 , ... ... Northern California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine ... dinner meeting. They observed that both STEMI and Sepsis conditions present in similar ways ...
(Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
(Date:11/26/2015)... Mass. (PRWEB) , ... November 26, 2015 , ... ... thorough second medical opinion process, participated in the 61st annual Employee Benefits Conference. ... Plans and took place Sunday, November 8th through Wednesday, November 11th, 2015. The ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
Breaking Medicine Technology: